Literature DB >> 15005282

Induction chemotherapy and radiotherapy in locally advanced non-small cell lung cancer.

Ezra E W Cohen1, Everett E Vokes.   

Abstract

The position for induction chemotherapy has shifted somewhat in the past few years. This approach has the ability to reduce distant failure and is relatively easy to administer. There are patients who would benefit from and could be offered induction chemotherapy--specifically, those who would not tolerate concurrent chemoradiotherapy or those who might benefit from more intensive therapy combing induction and concurrent strategies. The latter platform, however, should be undertaken with caution, ideally in a clinical trial setting.

Entities:  

Mesh:

Year:  2004        PMID: 15005282     DOI: 10.1016/s0889-8588(03)00148-5

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  2 in total

1.  Intratumoral chemotherapy with paclitaxel liposome combined with systemic chemotherapy: a new method of neoadjuvant chemotherapy for stage III unresectable non-small cell lung cancer.

Authors:  Bei Lu; Lixin Sun; Xi Yan; Zhenzhong Ai; Jinzhi Xu
Journal:  Med Oncol       Date:  2014-11-28       Impact factor: 3.064

2.  Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.

Authors:  Nicholas W Choong; Everett E Vokes; Daniel J Haraf; Peter K Tothy; Mark K Ferguson; Kristen Kasza; Charles M Rudin; Philip C Hoffman; Stuart A Krauss; Livia Szeto; Ann M Mauer
Journal:  J Thorac Oncol       Date:  2008-01       Impact factor: 15.609

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.